Download the Free Prime PubMed App to your smartphone or tablet.

Available for iPhone or iPad:

Unbound PubMed app for iOS iPhone iPadAlso Available:
Unbound MEDLINE
Unbound PubMed app for Android

Available for Mac and Windows Desktops and laptops:

Unbound PubMed app for WindowsUnbound PubMed app for MAC OS Yosemite Macbook Air pro
(CeeNu)
2,543 results
  • Prolonged Temozolomide Maintenance Therapy in Newly Diagnosed Glioblastoma. [Journal Article]
  • OOncologist 2017 Mar 30
  • Skardelly M, Dangel E, … Tabatabai G
  • CONCLUSIONS: Our data do not support a general extension of TMZ maintenance therapy beyond six cycles. The Oncologist 2017;22:1-6 IMPLICATIONS FOR PRACTICE: Radiation therapy with concomitant and adjuvant temozolomide (TMZ) maintenance therapy is still the standard of care in patients below the age of 65 years in newly diagnosed glioblastoma. However, in clinical practice, many centers continue TMZ maintenance therapy beyond six cycles. The impact of this continuation is controversial and has not yet been addressed in prospective randomized clinical trials. We compared the effect of more than six cycles of TMZ in comparison with exactly six cycles on overall survival (OS) and progression-free survival (PFS) by multivariate analysis and found a benefit in PFS but not OS. Thus, our data do not suggest prolonging TMZ maintenance therapy beyond six cycles, which should be considered in neurooncological practice.
  • Glioma Subclassifications and Their Clinical Significance. [Review]
  • NNeurotherapeutics 2017; 14(2):284-297
  • Chen R, Smith-Cohn M, … Colman H
  • The impact of targeted therapies in glioma has been modest. All the therapies that have demonstrated a significant survival benefit for gliomas in Phase III trials, including radiation, chemotherapy ...
  • Is CCNU (lomustine) valuable for treatment of cutaneous epitheliotropic lymphoma in dogs? A critically appraised topic. [Review]
  • BVBMC Vet Res 2017 Feb 21; 13(1):61
  • Laprais A, Olivry T
  • CONCLUSIONS: CCNU leads to a complete remission of signs in approximately one-third of dogs with CTCL, but such remissions are of short duration. The median survival time after CCNU appears longer than that without treatment, but other drugs appear to provide a better long-term prognosis. Further studies are required to investigate the effect of CCNU, alone or in combination, on remission rates, survival times and impact on quality of life.
New Search Next